Skip to main content
PLIANT THERAPEUTICS, INC. logo

PLIANT THERAPEUTICS, INC. — Investor Relations & Filings

Ticker · PLRX ISIN · US7291391057 LEI · 5493002Q5LITR7VHZH02 US Professional, scientific and technical activities
Open in API
Filings indexed 403 across all filing types
Latest filing 2022-09-14 Director's Dealing
Country US United States of America
Listing US PLRX

About PLIANT THERAPEUTICS, INC.

https://pliantrx.com/

Pliant Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies for the treatment of fibrosis and related diseases. The company leverages its expertise in integrin biology to create tissue-specific treatments. Its therapeutic approach centers on modulating integrin activity and inhibiting TGF-β1 signaling, which are key molecular drivers of fibrosis. Pliant utilizes its proprietary discovery platform to advance a pipeline of integrin-based product candidates, aiming to provide safer and more effective therapies for patients.

Recent filings

Filing Released Lang Actions
FORM 4
Director's Dealing
2022-09-14 English
SC 13G/A
Major Shareholding Notification
2022-08-31 English
Major Shareholding Notification 2022
Major Shareholding Notification
2022-08-10 English
10-Q
Interim / Quarterly Report Q2 2022
2022-08-08 English
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated August 8, 2022, reporting the company's financial results for the second quarter ended June 30, 2022. It includes a press release announcing these results but does not contain the full financial statements or detailed analysis itself. The document length is 3765 characters, which is relatively short and primarily serves as an announcement of the earnings release rather than the earnings release itself. According to the classification rules, initial announcements of quarterly financial results are classified as Earnings Release (ER). The presence of a press release announcing quarterly financial results aligns with the ER category.
2022-08-08 English
8-K
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content includes a financial update with preliminary estimates of cash and investments, details about an underwriting agreement for a public offering of common stock, and related legal opinions. There are no full financial statements or comprehensive financial analysis typical of an Annual Report (10-K) or Interim Report (IR). The document primarily announces a capital raising event and related agreements, which fits the category of Capital/Financing Update (CAP). The length is sufficient and the content is substantive, not merely an announcement of a report publication or a certification. Therefore, the best classification is CAP with high confidence.
2022-07-14 English

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.